Atossa Advances (Z)-Endoxifen With FDA-Backed Strategy to Accelerate Breast Cancer Development Pathways
Seattle, WA — December 4, 2025 Atossa Therapeutics has outlined an accelerated FDA regulatory strategy to advance its investigational therapy,...
Pharma
Advertisement
FDA Grants Orphan Drug Designation to J&D’s HCC Therapy, Accelerating New Options for Liver Cancer Treatment
Monmouth, NJ — December 4, 2025 J & D Pharmaceuticals LLC has received U.S. FDA Orphan Drug Designation for its...
ANI Pharmaceuticals to Present at Piper Sandler Conference
PRINCETON, N.J., Nov. 25, 2025 — ANI Pharmaceuticals’ announcement of its participation in the upcoming Piper Sandler 37th Annual...
Lilly Invests $6.5 B to Build API Plant in Houston
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
Merck’s CAPVAXIVE Shows Strong Immune Response in Children
RAHWAY, N.J. – September 11, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada,...
Advertisements
Lilly and Julianne Moore Team Up on “Brain Health Matters” Alzheimer’s Awareness Campaign
INDIANAPOLIS, Sept. 9, 2025, Eli Lilly and Company (NYSE: LLY) has launched a new global initiative, “Brain Health Matters,”...
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its risperidone...
FDA Clears WIDAPLIK™, Developed with Piramal Pharma Solutions
Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), has collaborated with George Medicines to develop WIDAPLIK™,...
Advertisement
